Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Feature|Articles|February 3, 2025
EltaMD Unveils Breakthrough Post-Procedure Sunscreen Clinically Proven to Repair and Protect Skin
Author(s)Emma Andrus, Editor
The clinically-backed, post-procedure sunscreen is designed to enhance skin healing, reduce redness, promote hydration, and provide broad-spectrum UV protection.
Advertisement
Advertisement
Patients recovering from laser treatments or struggling with rosacea often face a dual challenge: protecting compromised skin from UV damage while accelerating healing.
Related to this article
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement